ASYMCHEM LAB.(TIAN.)H YC1 Total Liabilities
ASYMCHEM LAB.(TIAN.)H YC1 total liabilities. Based on the latest financial reports, ASYMCHEM LAB.(TIAN.)H YC1 (7K90) has total liabilities worth €2.74 Billion EUR (≈ $3.21 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of ASYMCHEM LAB.(TIAN.)H YC1 to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)
Total liabilities of ASYMCHEM LAB.(TIAN.)H YC1 from 2021 to 2025. This chart illustrates how ASYMCHEM LAB.(TIAN.)H YC1's total liabilities have evolved over time, based on quarterly financial data.
ASYMCHEM LAB.(TIAN.)H YC1 Competitors by Total Liabilities
The table below lists competitors of ASYMCHEM LAB.(TIAN.)H YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kangxin New Materials Co Ltd
SHG:600076
|
China | CN¥2.99 Billion |
|
Dufu Tech Corp Bhd
KLSE:7233
|
Malaysia | RM98.73 Million |
|
Zhejiang Jinsheng New Materials Co
SHE:300849
|
China | CN¥191.82 Million |
|
Luoyang Glass
SHG:600876
|
China | CN¥10.33 Billion |
|
Keystone Technology Co Ltd
SHG:605588
|
China | CN¥1.91 Billion |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
USA | $34.24 Million |
|
Shanghai Ailu Package Co. Ltd.
SHE:301062
|
China | CN¥1.51 Billion |
|
China Datang Corporation Renewable Power Co. Limited
STU:DT7
|
Germany | €77.60 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ASYMCHEM LAB.(TIAN.)H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ASYMCHEM LAB.(TIAN.)H YC1 (7K90) total assets.
Liquidity & Leverage Metrics
ASYMCHEM LAB.(TIAN.)H YC1 Total Liabilities Ratios Explained
ASYMCHEM LAB.(TIAN.)H YC1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ASYMCHEM LAB.(TIAN.)H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)
The table below shows the annual total liabilities of ASYMCHEM LAB.(TIAN.)H YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.63 Billion ≈ $3.08 Billion |
+8.46% |
| 2024-12-31 | €2.43 Billion ≈ $2.84 Billion |
+7.48% |
| 2023-12-31 | €2.26 Billion ≈ $2.64 Billion |
-11.28% |
| 2022-12-31 | €2.54 Billion ≈ $2.97 Billion |
-0.08% |
| 2021-12-31 | €2.55 Billion ≈ $2.98 Billion |
-- |
About ASYMCHEM LAB.(TIAN.)H YC1
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more